Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)

Core Insights - Iovance Biotherapeutics (IOVA) has shown improvement in its Q2'25 earnings, indicating a positive step forward for the company [1] - Despite the progress, there are concerns regarding the previous challenges faced during the launch of Amtagvi, leading to a cautious stance on recommending the stock as a buy [1] Company Analysis - The company is involved in the biotech sector, focusing on trading around significant events such as trial results and NDA/BLA approvals [1] - There is a recognition of the regulatory environment, particularly the influence of the FDA on the company's operations and market performance [1]